Description: Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Home Page: www.shieldtherapeutics.com
Northern Design Centre
Gateshead,
NE8 3DF
United Kingdom
Phone:
44 1915 118 500
Officers
| Name | Title |
|---|---|
| Mr. Gregory P. Madison | CEO & Exec. Director |
| Dr. Christian Schweiger M.D., Ph.D. | Co-Founder & Non Exec. Director |
| Mr. Hans-Peter Rudolf | Chief Financial Officer |
| Ms. Lucy Huntington-Bailey | Gen. Counsel & Company Sec. |
| Ms. Suzanne Wood | Group HR Director |
| Ms. Carol Akinola | Head of Pharmacovigilance & Medical Information |
| Dr. José A. Menoyo M.D. | Chief Medical Officer |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 53.7634 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.746 |
| Price-to-Sales TTM: | 7.3708 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |